Skip to main content

Important Safety Information

Risk From Radiation Exposure
PLUVICTO contributes to a patient’s long-term cumulative radiation exposure, which is associated with an increased risk for cancer.

Minimize radiation exposure to patients, medical personnel, and household contacts during and after treatment with PLUVICTO consistent with institutional practices, patient treatment procedures, Nuclear...

Indication

PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION
References: 
1. Pluvicto. Prescribing information. Advanced Accelerator Applications USA, Inc. 2. Centers for Disease Control and Prevention. ALARA - as low as reasonably achievable. https://www.cdc.gov/nceh/radiation/alara.html . Accessed September 15, 2021. 3. Data on file. VISION [PSMA-617-01]. Novartis Pharmaceuticals Corp; 2021.